Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Brown, Jacquelyn A ^a   Sherrod, Stacy D ^a   Goodwin, Cody R ^a   Brewer, Bryson ^b   Yang, Lijie ^b   Garbett, Krassimira A ^a   Li, Deyu ^a,b   McLean, John A ^a   Wikswo, John P ^a,b,c   Mirnics, Károly ^a,d,e  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Glycerophospholipid; Immune activation; Interleukin; Kynurenine; Metabolomics; Microfluidics; Ultra performance liquid chromatography ion mobility mass spectrometry

Indexed keywords

GLYCEROPHOSPHOLIPID; INTERLEUKIN 6; KYNURENINE; TRYPTOPHAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; AUTISM; CELL ACTIVITY; CELL METABOLISM; CELL VOLUME; CELLULAR SECRETION; CELLULAR STRESS RESPONSE; CULTURE MEDIUM; DISEASE ASSOCIATION; EFFLUENT; EMBRYO; FEMALE; ION MOBILITY SPECTROMETRY; LIPID METABOLISM; MALE; MASS SPECTROMETRY; METABOLOME; MICROFLUIDIC ANALYSIS; MOUSE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL STIMULATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; SCHIZOPHRENIA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; METABOLISM; NERVE CELL;

ANIMALS; ASTROCYTES; CELLS, CULTURED; FEMALE; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICROFLUIDIC ANALYTICAL TECHNIQUES; NEURONS;

EID: 84920769320     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0183-6     Document Type: Article

References (74)

1. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007, 62:711-721.
2. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, Blencowe BJ, Geschwind DH: Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380-384.
3. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, Persico AM: Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008, 30:303-311.
4. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, Mirnics K: Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2010, 16:751-762.
5. Ganguly D, Haak S, Sisirak V, Reizis B: The role of dendritic cells in autoimmunity. Nat Rev Immunol 2013, 13:566-577.
6. Horvath S, Mirnics K: Immune system disturbances in schizophrenia. Biol Psychiatry 2014, 75:316-323.
7. Michel M, Schmidt MJ, Mirnics K: Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol 2012, 72:1277-1287.
8. Shi L, Fatemi SH, Sidwell RW, Patterson PH: Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003, 23:297-302.
9. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH: Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci U S A 2012, 109:12776-12781.
10. Shi L, Tu N, Patterson PH: Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. Int J Dev Neurosci 2005, 23:299-305.
11. Patterson PH: Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009, 204:313-321.
12. Garbett KA, Hsiao EY, Kalman S, Patterson PH, Mirnics K: Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl Psychiatry 2012, 2:e98.
13. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007, 27:10695-10702.
14. Hsiao EY, Patterson PH: Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun 2011, 25:604-615.
15. Erta M, Quintana A, Hidalgo J: Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012, 8:1254-1266.
16. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, Gerlo S: Interleukin-6, a mental cytokine. Brain Res Rev 2011, 67:157-183.
17. Stolp HB: Neuropoietic cytokines in normal brain development and neurodevelopmental disorders. Mol Cell Neurosci 2012, 53:63-68.
18. Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, Matloff WJ: Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip 2013, 13:3496-3511.
19. Faley S, Seale K, Hughey J, Schaffer DK, VanCompernolle S, McKinney B, Baudenbacher F, Unutmaz D, Wikswo JP: Microfluidic platform for real-time signaling analysis of multiple single T cells in parallel. Lab Chip 2008, 8:1700-1712.
20. Enders JR, Marasco CC, Wikswo JP, McLean JA: A dual-column solid phase extraction strategy for online collection and preparation of continuously flowing effluent streams for mass spectrometry. Anal Chem 2012, 84:8467-8474.
21. Brown JA, Diggs-Andrews KA, Gianino SM, Gutmann DH: Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCKdependent manner. Mol Cell Neurosci 2011, 49:13-22.
22. Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL: Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J Neurosci Res 1994, 38:248-258.
23. Kerrison JB, Zack DJ: Neurite outgrowth in retinal ganglion cell culture. Methods Mol Biol 2007, 356:427-434.
24. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM, Gutmann DH: Differential effects of cAMP in neurons and astrocytes. Role of B-raf J Biol Chem 1999, 274:25842-25848.
25. Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH: Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res 2007, 67:4790-4799.
26. Dugan JP, Stratton A, Riley HP, Farmer WT, Mastick GS: Midbrain dopaminergic axons are guided longitudinally through the diencephalon by Slit/Robo signals. Mol Cell Neurosci 2011, 46:347-356.
27. McDonald JC, Whitesides GM: Poly(dimethylsiloxane) as a material for fabricating microfluidic devices. Acc Chem Res 2002, 35:491-499.
28. Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE: Soft lithography in biology and biochemistry. Annu Rev Biomed Eng 2001, 3:335-373.
29. Shi M, Majumdar D, Gao Y, Brewer BM, Goodwin CR, McLean JA, Li D, Webb DJ: Glia co-culture with neurons in microfluidic platforms promotes the formation and stabilization of synaptic contacts. Lab Chip 2013, 13:3008-3021.
30. Gao Y, Majumdar D, Jovanovic B, Shaifer C, Lin PC, Zijlstra A, Webb DJ, Li D: A versatile valve-enabled microfluidic cell co-culture platform and demonstration of its applications to neurobiology and cancer biology. Biomed Microdevices 2011, 13:539-548.
31. Brewer BM, Shi M, Edd JF, Webb DJ, Li D: A microfluidic cell co-culture platform with a liquid fluorocarbon separator. Biomed Microdevices 2014, 16(2):311-323.
32. Kuehn H, Liberzon A, Reich M, Mesirov JP: Using GenePattern for gene expression analysis. Curr Protoc Bioinformatics 2008, Chapter 7:Unit 7 12.
33. Kessner D, Chambers M, Burke R, Agus D, Mallick P: ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 2008, 24:2534-2536.
34. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, Siuzdak G: METLIN: a metabolite mass spectral database. Ther Drug Monit 2005, 27:747-751.
35. Wishart DS: Current progress in computational metabolomics. Brief Bioinform 2007, 8:279-293.
36. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, Merrill AH Jr, Murphy RC, Raetz CR, Russell DW, Subramaniam S: LMSD: LIPID MAPS structure database. Nucleic Acids Res 2007, 35:D527-D532.
37. da Costa KA, Rai KS, Craciunescu CN, Parikh K, Mehedint MG, Sanders LM, McLean-Pottinger A, Zeisel SH: Dietary docosahexaenoic acid supplementation modulates hippocampal development in the Pemt-/-mouse. J Biol Chem 2010, 285:1008-1015.
38. Myint AM, Schwarz MJ, Muller N: The role of the kynurenine metabolism in major depression. J Neural Transm 2011, 119:245-251.
39. Janssen CI, Kiliaan AJ: Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res 2013, 53C:1-17.
40. Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, Magalhaes PV, Kapczinski F: Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother 2013, 13:827-842.
41. Muller N, Myint AM, Schwarz MJ: Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011, 17:130-136.
42. McIntyre TM: Bioactive oxidatively truncated phospholipids in inflammation and apoptosis: formation, targets, and inactivation. Biochim Biophys Acta 2012, 1818:2456-2464.
43. Schwarcz R, Pellicciari R: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
44. Oxenkrug GF: Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 2010, 47:56-63.
45. Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, Gardner R, Lundkvist GB, Urbanska EM, Karlsson H: Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res 2013, 47:1815-1823.
46. Doering LC (Ed): Protocols for Neural Cell Culture. 4th edition. New York: Humana Press; 2010.
47. Ji R, Tian S, Lu HJ, Lu Q, Zheng Y, Wang X, Ding J, Li Q: TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J Immunol 2013, 191:6165-6177.
48. Losino N, Waisman A, Solari C, Luzzani C, Espinosa DF, Sassone A, Muro AF, Miriuka S, Sevlever G, Baranao L, Guberman A: EDA-containing fibronectin increases proliferation of embryonic stem cells. PLoS One 2013, 8:e80681.
49. Rao KM, Ma JY, Meighan T, Barger MW, Pack D, Vallyathan V: Time course of gene expression of inflammatory mediators in rat lung after diesel exhaust particle exposure. Environ Health Perspect 2005, 113:612-617.
50. Wei F, Guo W, Zou S, Ren K, Dubner R: Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci 2008, 28:10482-10495.
51. Polazzi E, Contestabile A: Neuron-conditioned media differentially affect the survival of activated or unstimulated microglia: evidence for neuronal control on apoptotic elimination of activated microglia. J Neuropathol Exp Neurol 2003, 62:351-362.
52. Morell P, Ousley AH: Metabolic turnover of myelin glycerophospholipids. Neurochem Res 1994, 19:967-974.
53. Lee C, Fisher SK, Agranoff BW, Hajra AK: Quantitative analysis of molecular species of diacylglycerol and phosphatidate formed upon muscarinic receptor activation of human SK-N-SH neuroblastoma cells. J Biol Chem 1991, 266:22837-22846.
54. Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA: Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 2011, 50:313-330.
55. Chen C, Bazan NG: Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 2005, 77:65-76.
56. Lopresti AL, Maker GL, Hood SD, Drummond PD: A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry 2013, 48:102-111.
57. Najjar S, Pearlman DM, Hirsch S, Friedman K, Strange J, Reidy J, Khoukaz M, Ferrell RB, Devinsky O, Najjar A, Zagzag D: Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. Biol Psychiatry 2014, 75:e23-e26.
58. Wu JQ, Kosten TR, Zhang XY: Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:200-206.
59. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Federoff HJ: Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014, 20(4):415-418.
60. Stone TW: Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs 2001, 10:633-645.
61. Freese A, Swartz KJ, During MJ, Martin JB: Kynurenine metabolites of tryptophan: implications for neurologic diseases. Neurology 1990, 40:691-695.
62. Stone TW, Forrest CM, Darlington LG: Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 2012, 279:1386-1397.
63. Dantzer R, O'Connor JC, Lawson MA, Kelley KW: Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2010, 36:426-436.
64. Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schule C, Zill P, Muller N, Rupprecht R, Schwarz MJ: Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav Immun 2013, 31:128-133.
65. Munn DH, Mellor AL: Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
66. Jain A, Munn LL: Biomimetic postcapillary expansions for enhancing rare blood cell separation on a microfluidic chip. Lab Chip 2011, 11:2941-2947.
67. Oxenkrug G: Serotonin-kynurenine hypothesis of depression: historical overview and recent developments. Curr Drug Targets 2013, 14:514-521.
68. Myint AM: Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012, 279:1375-1385.
69. Plangar I, Zadori D, Klivenyi P, Toldi J, Vecsei L: Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. J Alzheimers Dis 2011, 24(Suppl 2):199-209.
70. Alcendor DJ, Block FE III, Cliffel DE, Daniels JS, Ellacott KL, Goodwin CR, Hofmeister LH, Li D, Markov DA, May JC, McCawley LJ, McLaughlin B, McLean JA, Niswender KD, Pensabene V, Seale KT, Sherrod SD, Sung HJ, Tabb DL, Webb DJ, Wikswo JP: Neurovascular unit on a chip: implications for translational applications. Stem Cell Res Ther 2013, 4(Suppl 1):S18.
71. Burton MD, Sparkman NL, Johnson RW: Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharideinduced sickness behavior. J Neuroinflammation 2011, 8:54.
72. Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, Scheller J, Hidalgo J: Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 2014, 34:2503-2513.
73. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ: Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species. Prog Neurobiol 2013, 106-107:1-16.
74. Trapero I, Cauli O: Interleukin 6 and cognitive dysfunction. Metab Brain Dis 2014, 29:593-608.